This clinical trial is focused on studying the effects of a treatment for Alzheimer’s Disease, a condition that affects memory and thinking skills. The treatment being tested is called Donanemab, which is an antibody designed to target a protein known as amyloid beta, believed to play a role in Alzheimer’s. The study will also involve the use of two imaging agents, Florbetapir and Flortaucipir, which are solutions injected into the body to help visualize certain brain changes associated with Alzheimer’s.

The purpose of this study is to assess how Donanemab affects the progression of early symptomatic Alzheimer’s Disease compared to a placebo. Participants will receive either the treatment or a placebo through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants over a period to observe any changes in their condition.

Throughout the study, participants will undergo various assessments, including brain scans using Florbetapir and Flortaucipir, to evaluate the treatment’s impact on Alzheimer’s Disease. These scans help researchers see how the disease progresses and how the treatment might alter this progression. The study aims to provide valuable insights into the safety and effectiveness of Donanemab in managing early Alzheimer’s symptoms.